Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma on December 31, 2027. There are 3 upcoming events on record.
Cash runway is approximately 22.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 31, 2027 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | Trial Milestone | Phase 1/Phase 2 |
| January 31, 2028 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
| November 26, 2029 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | Trial Milestone | Phase 1/Phase 2 |
Track CATX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CATX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| October 8, 2026 | 8-K filed: Other event | Filing | — |
| October 1, 2026 | 8-K filed: Other event | Filing | — |
| September 14, 2026 | 8-K filed: Other event | Filing | — |
| September 8, 2026 | 8-K filed: Other event | Filing | — |
| August 10, 2026 | Quarterly results filed (8-K) | Earnings | — |
| August 3, 2026 | 8-K filed: Other event | Filing | — |
| July 1, 2026 | 8-K filed: Other event | Filing | — |
| June 1, 2026 | 8-K filed: Other event | Filing | — |
| May 22, 2026 | 8-K filed: Other event | Filing | — |
| May 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 4, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 20, 2026 | 8-K filed: Other event | Filing | — |
| April 1, 2026 | 8-K filed: Other event | Filing | — |
| March 16, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 3, 2026 | 8-K filed: Material agreement, Other event | Corporate | — |
| February 2, 2026 | Quarterly results filed (8-K) | Earnings | — |
| January 14, 2026 | 8-K filed: Other event | Filing | — |
| January 12, 2026 | 8-K filed: Other event | Filing | — |
| January 9, 2026 | Quarterly results filed (8-K) | Earnings | — |
| December 1, 2025 | 8-K filed: Other event | Filing | — |
| November 10, 2025 | Quarterly results filed (8-K) | Earnings | — |
| November 6, 2025 | 8-K filed: Other event | Filing | — |
| November 3, 2025 | 8-K filed: Leadership change | Corporate | — |
| October 20, 2025 | Quarterly results filed (8-K) | Earnings | — |
| October 1, 2025 | 8-K filed: Other event | Filing | — |
| September 4, 2025 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| September 3, 2025 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| September 2, 2025 | 8-K filed: Other event | Filing | — |
| August 13, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 1, 2025 | 8-K filed: Other event | Filing | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.